Document is current

Any future updates will be listed below

Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20+

Crossref DOI link: https://doi.org/10.1007/s00277-025-06332-y

Published Online: 2025-05-16

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark